1. Harris N, Jaffe E, Diebold J, et al. World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-3849.
2. Harris NL, Jaffe ES, Stein H, et al. A revised european-american classification of lymphoid neoplasms: a proposal from the international lymphoma study group. Blood 1994;84:1361-1392.
3. Di Giuseppe JA, Borowitz MJ. Clinical utility of flow cytometry in the chronic lymphoid leukemias. Semin Oncol 1998;25:6-10.
4. Stetler-Stevenson M, Braylan RC. Flow cytometric analysis of lymphomas and lymphoproliferative disorders. Semin Hematol 2001;38:2111-2123.
5. Jennings CD, Foon KA. Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy. Blood 1997;90:2863-2892.
6. Matutes E, Polliack A. Morphological and immunophenotypic features of chronic lymphocytic leukemia. Rev Clin Exp Hematol 2000;4:22-47.
7. Matutes E. Contribution of immunophenotype in the diagnosis and classification of haemapoietic malignancies. J Clin Pathol 1995;48:194-197.
8. Montserrat E. Chronic lymphoproliferative disorders. Curr Opin Oncol 1997;9:34-41.
9. Rawstron AC, Kennedy B, Evans PA, et al. Quantification of minimal residual disease levels in chronic lympho-cytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001;98:29-35.
10. Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma and small B-cell lymphocytic lymphoma. J Clin Oncol 2000;18:317-324.
11. Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in loss of CD20 antigen expression. Clin Cancer Res 1999;5:611-615.
12. Foran JM, Norton AJ, Micallef IN, et al. Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis. Br J Haematol 2001;114:881-883.
13. Samoilava RS. Possibilities of differential diagnosis of B-cell chronic lymphoproliferative diseases using monoclonal antibodies. Gematol Transfuzion 1990;35:24-27.
14. Rothe G, Schmitz G. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Working Group on Flow Cytometry and Image Analysis. Leukemia 1996;10:877-895.
15. Davis BH, Foucar K, Szczarkowski W, et al. U.S.-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: medical indications. Cytometry 1997;30:249-263.
16. Whiteside TL. Basic techniques for the detection of human T and B lymphocytes in tissues. Clin Immunol News 1980;1:1-15.
17. Orfao A, Schmitz G, Brando B, et al. Clinically useful information provided by the flow cytometric immunophenotyping of haematological malignancies: current status and future directions. Clin Chem 1999;45: 1708-1717.
18. Geary W, Frierson HF, Innes DJ, et al. Quantitative criteria for clonality in the diagnosis of B-cell non-Hodgkin's lymphoma by flow cytometry. Mod Pathol 1993;6:155-161.
19. Peters R, Janossy G, Ivory K, et al. Leukemia-associated changes identified by quantitative flow cytometry. III. B-cell gating in CD37 k/A clonality test. Leukemia 1994;8:1864-1870.
20. Fend F, Quintanilla-Martinez L, Kumar S, et al. Composite low grade B-cell lymphomas with two immuno-phenotypically distinct cell populations are true biclonal lymphomas. A molecular analysis using laser capture microdissection. Am J Pathol 1999;154:1857-1866.
21. Sanchez ML, Almeida J, Gonzalez D, et al. Incidence and clinico-biologic characteristics of biclonality in leukemic B-cell Chronic lymphoproliferative disorders (B-CLPD). In: Proceedings of the 7th Congress of the European Hematology Association (abstract).
22. Ciudad J, San Miguel JF, Lopez-Berges MC, et al. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia. J Clin Oncol 1998;16:3774-3781.
23. San Miguel JF, Martinez A, Macedo A, et al. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 1997;90:2465-2470.
24. Coustan-Smith E, Behm FG, Sanchez J, et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 1998;351:550-554.
25. Sanchez ML, Almeida J, Vidriales B, et al. Incidence of phenotypic aberrations in a series of 467 patients with B-chronic lymphoproliferative disorders: basis for the design of specific 4-color stainings to be used for minimal residual disease investigation. Leukemia 2002;16:1460-1469.
26. Wells DA, Hall MC, Shulman HM, Loken MR. Occult B cell malignancies can be detected by three-color flow cytometry in patients with cytopenias. Leukemia 1998;12:2015-2023.
27. Chan LC, Lam CK, Yeung TC, et al. The spectrum of chronic lymphoproliferative disorders in Hong Kong. A prospective study. Leukemia 1997;11:1964-1972.
28. Deneys V, Mazzon AM, Marques JL, Benoit H, De Bruyere M. Reference values for peripheral blood B-lympho-cyte subpopulations: a basis for multiparametric immunophenotyping of abnormal lymphocytes. J Immunol Methods 2001;253:23-36.
29. Haase D, Feuring-Buske M, Schafer C, et al. Cytogenetic analysis of CD34+ subpopulations in AML and MDS characterized by the expression of CD38 and CD117. Leukemia 1997;11:674-679.
30. Wuchter C, Harbott J, Schoch C, et al. Detection of acute leukemia cells with mixed lineage leukemia (MLL) gene rearrangements by flow cytometry using monoclonal antibody 7.1. Leukemia 2000;14:1232-1238.
31. Groeneveld K, te Marvelde JG, van den Beemd MW, Hooijkaas H, van Dongen JJ. Flow cytometric detection of intracellular antigens for immunophenotyping of normal and malignant leukocytes. Leukemia 1996;10: 1383-1389.
32. Lucio P, Parreira A, van den Beemd MWM, et al. Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B ALL. Leukemia 1999;13: 419-427.
33. Dworzak MN, Fritsch G, Froschl G, Printz D, Gadner H. Four-color flow cytometric investigation of terminal deoxynucleotidyl transferase-positive lymphoid precursors in pediatric bone marrow: CD79a expression precedes CD19 in early B-cell ontogeny. Blood 1998;92:3203-3209.
34. Ciudad J, Orfao A, Vidriales B, et al. Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: implications for minimal residual disease detection. Haematologica 1998;83:1069-1075.
35. De Waele M, Renmans W, Jochmans K, et al. Different expression of adhesion molecules on CD34+ cells in AML and B-lineage ALL and their normal bone marrow counterparts. Eur J Haematol 1999;63:192-201.
36. Weir EG, Cowan K, LeBeau P, Borowitz MJ. A limited antibody panel can distinguish B-precursor acute lympho-blastic leukemia from normal B precursors with four color flow cytometry: implications for minimal residual disease detection. Leukemia 1999;13:558-567.
37. Agematsu K. Memory B-cells and CD27. Histol Histopathol 2000;15:573-576.
38. Jacquot S. CD27/CD70 interactions regulate T dependent B-cell differentiation. Immunol Res 2000;21:23-30.
39. Tangye SG, Liu YJ, Aversa G, Philips JH, de Vries JE. Identification of functional human splenic memory B cells by expression of CD148 and CD27. J Exp Med 1998;188:1691-1703.
40. Klein U, Goossens T, Fischer M, et al. Somatic hypermutation in normal and transformed human B cells. Immunol Rev 1998;162:261-280.
41. Klein U, Jajewski K, Kuppers R. Human immunoglobulin (Ig)M+ IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J Exp Med 1998;188:1679-1689.
42. Klein U, Kuppers R, Jajewski K. Evidence for a large compartment of IgM-expressing memory B cells in humans. Blood 1997;89:1288-1298.
43. Klein U, Rajewsky, Küppers R. Phenotypic and molecular characterization of human peripheral blood B-cell subsets with special reference to N-region addition and J kappa -usage in V B-cell- subsets to identify traces of receptor editing processes. Curr Top Microbiol Immunol 1999;246:141-147.
44. Matutes E, Owusuankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994;8:1640-1645.
45. Bennet JM, Catovsky D, Daniel MT, et al. Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. J Clin Pathol 1989;42:567-584.
46. Matutes E, Worner I, Sainati L, de Olivera MP, Cayovsky D. Advances in the lymphoproliferative disorders. Review of our experience in the study of over 1000 cases. Biol Clin Hematol 1989;11:53-62.
47. Matutes E. Immunophenotype of the chronic lymphoproliferative disorders. Haematologica 1998;83(suppl): 193-198.
48. Matutes E, Morilla R, Owusu-Ankomah K, et al. The immunophenotype of hairy-cell leukemia (HCL) -Proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes. Leuk Lymph 1994;14:57-61.
49. Trentin L, Zambello R, Sancetta R, et al. B lymphocytes from patients with chronic lymphoproliferative disorders are equipped with different costimulatory molecules. Cancer Res 1997;57:4940-4947.
50. Deneys V, Michaux L, Leveugle P, et al. Atypical lymphocytic leukemia and mantle cell lymphoma immunologically very close: flow cytometric distinction by use of CD20 and CD54 expression. Leukemia 2001;15:1458-1465.
51. Moreau E, Matutes E, a'Hern RP, et al. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antobody SN8 (CD79b). Am J Clin Pathol 2000;108:378-382.
52. Braylan RC, Orfao A, Borowitz MJ, Davis BH. Optimal number of reagents required to evaluate hematolymphoid neoplasias: Results of an International Consensus Meeting. Cytometry 2001;46:23-27.
53. Catovsky D. Chronic lymphoproliferative disorders. Curr Opin Oncol 1995;7:3-11.
54. Melo JV, Catovsky D, Galton DAG. The relationship between chronic lymphocytic leukemia and prolymphocytic leukaemia. I. Clinical and laboratory features of 300 patients and characterization of an intermediate group. Br J Haematol 1986;63:377-387.
55. Orfao A, Gonzalez M, San Miguel JF, et al. Clinical and immunological findings in large B-cell chronic lymphocytic leukemia. Clin Immunol Immunopahol 1988;46:177-185.
56. Marotta G, Raspadori D, Sestigiani C, Scalia G, Biqazzi C, Lauria F. Expression of the CD11c antigen in B-cell chronic lymphoproliferative disorders. Leuk Lymph 2000;37:145-149.
57. Melo JV, Catovsky D, Galton DA. The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. II. Patterns of evolution of "prolymphocytoid" transformation. Br J Haematol 1986;64:77-86.
58. Melo JV, Wardle J, Chetty M, et al. The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. III. Evaluation of cell size by morphology and volume measurements. Br J Haematol 1986;84:469-478.
59. Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood 1958;13:609-615.
60. Bouroncle BA. Leukemic reticuloendotheliosis (Hairy-cell leukemia). Blood 1979;53:412-436.
61. Bouroncle BA. Clínica, biología y formas variantes de tricoleucemia. In: Lopez Borrasca, et al. Enciclopedia de Hematologia Iberoamericana (EHIA). Universidad de Salamanca, Salamanca, 1992.
62. Frassoldati A, Lamparelli T, Federico M, et al. Hairy cell leukemia: a clinical review based on 725 cases of the Italian Cooperative Group (ICGHCL). Leuk Lymph1994;13:307-316.
63. Troussard X, Maloisel F, Flandrin G. Hairy cell leukemia. What is new forty years after the first description? Hematol Cell Ther 1998;40:139-148.
64. Polliack A. Hairy cell leukemia and allied chronic lymphoid leukemias: current knowledge and new therapeutic options. Leuk Lymph 1997;26:41-51.
65. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995;333:1052-1057.
66. Ahmad E, Garcia D, Davis BH. Clinical utility od CD23 and FMC7 antigen coexistent expression in B-cell lymphoproliferative disorder subclassification. Cytometry 2002;50:1-7.
67. Melo JV, San Miguel JF, Moss VE, Catovsky D. The membrane phenotype of hairy cells: a study with monoclonal antibodies. Semin Oncol 1984;11:381-385.
68. Bain BJ, Catovsky D. The leukaemic phase of non-Hodgkin's lymphoma. J Clin Pathol 1995;48:189-193.
69. Lopez-Guillermo A, Cabanillas F, McLaughlin P, et al. Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: update of the MDACC series. Ann Oncol 2000;11(suppl 1):137-140.
70. Almasri NM, Iturraspe JA, Braylan RC. CD10 expression in follicular lymphoma and large cell lymphoma is different from that of reactive lymph node follicles. Arch Pathol Lab Med 1998;122:539-544.
71. Cao J, Vescio RA, Rettig MB, et al. A CD10-positive subset of malignant cells is identified in multiple myeloma using PCR with patient-specific immunoglobulin gene primers. Leukemia 1995;9:1948-1953.
72. San Miguel JF, Gonzalez M, Gascon A, et al. Immunophenotypic heterogeneity of multiple myeloma: influence on the biology and clinical course of the disease. Castellano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammapathies. Br J Haematol 1991;77:185-190.
73. Bellido M, Rubiol E, Ubeda J, et al. Flow cytometry using the monoclonal antibody CD10-PE/Cy5 is a useful tool to identify follicular lymphoma cells. Eur J Haematol 2001;66:100-106.
74. Sun Y, Wyatt RT, Bigley A, Krontiris TG. Expression and replication timing patterns of wildtype and translocated BCL2 genes. Genomics 2001;73:161-170.
75. Cornfield DB, Mitchell DM, Almasri NM, et al.: Follicular lymphoma can be distinguished from benign follicular hyperplasia by flow cytometry using simultaneous staining of cytoplasmic bcl-2 and cell surface CD20. Am J Clin Pathol 2000;114:258-263.
76. Rodriguez J, McLaughlin P, Fayad L, et al. Follicular large cell lymphoma: long-term follow-up of 62 patients treated between 1973-1981. Ann Oncol 2000;11:1551-1556.
77. Weisenburger D, Armitage JO. Mantle cell lymphoma: an entity comes of age. Blood 1996;87:4483-4494.
78. Kurtin PJ. Mantle cell lymphoma. Adv Anat Patholo 1998;5:376-398.
79. Elnenaei MO, Jadayer DM, Matutes E, et al. Cyclin D1 by flow cytometry as a useful tool in the diagnosis of B-cell maligancies. Leuk Res 2001;25:115-123.
80. Matutes E, Morilla R, Owusu-Ankomah K, Houlihan A, Catovsky D. The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disorders. Blood 1994; 83:1558-1562.
81. Catovsky D, Matutes E. Splenic lymphoma with circulating villous lymphocytes/splenic marginal-zone lymphoma. Semin Hematol 1999;36:148-154.
82. Trourssard X, Valensi F, Duchayne E, et al. Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Br J Haematol 1996;93:731-736.
83. Kramer PA, Oosterhuis WP,Vankammen E, et al. A patient with a variant form of hairy-cell leukemia. Nether J Med 1993;43:262-268.
84. Matutes E, Meeus P, Mc Lennan K, Catovsky D. The significance of minimal residual disease in hairy cell leukaemia treated with deoxycoformycin: a long-term follow-up study. Br J Haematol 1997;98:375-387.
85. Bossuyt X, Bogaerts A, Schiettekatte G, Blanckaert N. Serum protein electrophoresis and immunofixation by a semiautomated electrophoresis system. Clin Chem 1998;44:944-949.
86. Iida S, Rao P, Nallasivam P, et al. The t(9;14) (p13;q32) chromosomal translocation associated with lympho-plasmacytic lymphoma involves the PAX-5 gene. Blood 1996;88:4110-4117.
87. Jacob MC, Agrawal S, Chaperot L, et al. Quantification of cellular adhesion molecules on malignant B cells from non-Hodgkin's lymphoma. Leukemia 1999;13:1428-1433.
88. Czader M, Porwit A, Tani E, Ost A, Mazur J, Auer G. DNA image cytometry and the expression of proliferative markers (proliferating cell nuclear antigen and Ki67) in non-Hodgkin's lymphomas. Mod Pathol 1995;8:51-58.
89. Winter JN, Andersen J, Variakojis D, et al. Prognostic implications of ploidy and proliferative activity in the diffuse, aggresive non-Hodgkin's lymphomas. Blood 1996;88:3919-3125.
90. Subira D, Castanon S, Aceituno E, et al. Flow cytometric analysis of cerebrospinal fluid samples and its utility in routine clinical practice. Am J Clin Pathol 2002;117:952-958.
91. Cabezudo E, Matutes E, Ramrattan M, Morilla R, Catovsky D. Analysis of residual disease in chronic lymphocytic leukemia by flow cytometry. Leukemia 1997;11:1909-1914.
92. Lenormand B, Bizet M, Fruchart C, et al. Residual disease in B-cell chronic lymphocytic leukemia patients and prognostic value. Leukemia 1994;8:1019-1026.
93. Garcia-Vela A, Delgado I, Benito L, et al. CD79b expression in B cell chronic lymphocytic leukemia: its implication for minimal residual disease detection. Leukemia 1999;13:1501-1505.
94. Ocqueteau M, Orfao A, Garcia R, San Miguel JF. Detection of monoclonality in bone marrow plasma cells by flow cytometry: limitations for minimal residual disease detection. Br J Haematol 1996;93:251-252.
95. Terol MJ, Lopez-Guillermo A, Bosh F, et al. Expression of beta-integrin adhesion molecules in non-Hodgkin's lymphoma: correlation with clinical and evolutive features. J Clin Oncol 1999;17:1869-1875.
96. Keating MJ. Chronic lymphocytic leukemia. Semin Oncol 1999;26:107-114.
Clinical Aspects: Prognosis
Was this article helpful?